Gastric Cancer Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, and Surgery), By End User (Ambulatory Surgery Centers, Hospitals and Specialty Clinics, and Other), By Region and Competition 2018-2028

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

 

Forecast Period

2024-2028

Market Size (2022)

USD 3.51 billion

CAGR (2023-2028)

6.13%

Fastest Growing Segment

Targeted Therapy

Largest Market

North America

 

Market Overview

Global Gastric Cancer Therapy Market has valued at USD 3.51 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 6.13% through 2028. The Global Gastric Cancer Therapy Market revolves around the diagnosis, treatment, and management of gastric cancer, also known as stomach cancer. Gastric cancer is a malignant tumor that develops in the lining of the stomach. This market encompasses a range of therapeutic interventions, diagnostic tools, and supportive care options aimed at combating the disease at various stages. The market is characterized by a variety of treatment modalities, including surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, and combination therapies. Surgery involves the removal of cancerous tissue and, in some cases, parts of the stomach. Chemotherapy and radiation therapy are used to shrink tumors and eliminate cancer cells. Targeted therapies focus on specific molecular targets, inhibiting tumor growth and spread.

Immunotherapies harness the immune system to target and destroy cancer cells. The market's growth is driven by factors such as the rising incidence of gastric cancer, particularly in certain regions with high prevalence, and increased awareness leading to early diagnosis. Advances in medical technology, the emergence of precision medicine, and ongoing research contribute to the development of more effective and personalized treatment approaches. Collaborations between pharmaceutical companies, research institutions, and healthcare providers enhance the availability of innovative therapies. However, challenges such as treatment resistance, high treatment costs, and limited access to advanced therapies in some regions influence market dynamics. Patient-centered care, supportive care options to manage treatment side effects, and the integration of biomarkers for early detection are also important considerations within the market. In conclusion, the Global Gastric Cancer Therapy Market addresses the critical need for effective diagnostics, treatment options, and supportive care measures for patients diagnosed with gastric cancer. Advances in medical science, increasing awareness, and collaborative efforts continue to shape the market's landscape, striving to improve patient outcomes and quality of life.

Key Market Drivers

Rising Incidence of Gastric Cancer

The rising incidence of gastric cancer is a significant concern within the Global Gastric Cancer Therapy Market. This increase can be attributed to various factors, including changing lifestyles, dietary habits, and population demographics. Gastric cancer, also known as stomach cancer, often develops over years, making its incidence sensitive to long-term lifestyle choices and environmental influences. Unhealthy diets high in processed foods, low in fruits and vegetables, and rich in salted and smoked foods have been linked to a higher risk of gastric cancer. Additionally, infection with the Helicobacter pylori bacterium, a known risk factor, plays a role in some cases. The rise in obesity rates and sedentary lifestyles further contribute to this upward trend. Urbanization and industrialization often lead to dietary shifts and increased exposure to environmental pollutants, both of which impact gastric cancer risk. Furthermore, an aging global population means more individuals are entering the age range where the risk of gastric cancer is higher. As the incidence of gastric cancer continues to rise, the demand for effective therapies and innovative treatment approaches also grows. The Global Gastric Cancer Therapy Market must address this challenge by emphasizing early detection through improved diagnostic methods, implementing public health campaigns to promote healthy lifestyles, and developing targeted and personalized treatment strategies to effectively combat this aggressive form of cancer.

Advancements in Diagnostic Technologies

Advancements in diagnostic technologies are playing a pivotal role in shaping the Global Gastric Cancer Therapy Market. These innovations are transforming the way gastric cancer is detected, diagnosed, and managed, ultimately leading to improved patient outcomes. State-of-the-art diagnostic tools such as endoscopy with high-definition imaging provide detailed visualization of the stomach lining, allowing for the identification of early-stage lesions and abnormalities. Advanced imaging techniques like positron emission tomography (PET) scans and magnetic resonance imaging (MRI) contribute to accurate staging and monitoring of disease progression. Molecular biomarker analysis is revolutionizing diagnosis by identifying specific genetic and molecular alterations associated with gastric cancer. This approach aids in early detection, risk assessment, and prediction of treatment response.

Liquid biopsies, which analyze circulating tumor DNA, offer a minimally invasive way to monitor treatment efficacy and detect recurrence. Moreover, the integration of artificial intelligence (AI) and machine learning enhances diagnostic accuracy. AI algorithms can analyze vast datasets to identify subtle patterns and features indicative of gastric cancer, enabling earlier and more precise diagnoses. The global shift towards telemedicine and digital health solutions is facilitating remote consultations, second opinions, and access to expert advice, particularly in regions with limited healthcare infrastructure. These advancements empower clinicians to make informed treatment decisions, enable early detection of gastric cancer, and contribute to the development of personalized therapeutic approaches. As diagnostic technologies continue to evolve, they are reshaping the landscape of the Gastric Cancer Therapy Market by promoting early intervention, accurate staging, and tailored treatment strategies for better patient outcomes.

Innovations in Therapeutic Approaches

Innovations in therapeutic approaches are driving significant transformations in the Global Gastric Cancer Therapy Market. These advancements are revolutionizing the treatment landscape for gastric cancer patients, offering more effective and tailored interventions. Immunotherapies, particularly immune checkpoint inhibitors, are gaining prominence. These therapies harness the immune system to target and attack cancer cells. Monoclonal antibodies that inhibit checkpoint proteins like PD-1 and CTLA-4 have shown remarkable success in extending survival and improving outcomes in advanced gastric cancer cases. Targeted therapies are being developed to specifically address molecular alterations driving gastric cancer growth. These therapies disrupt signaling pathways, such as HER2-targeted agents, aimed at tumors with HER2 overexpression. Similarly, VEGF inhibitors target blood vessel formation crucial for tumor growth. Precision medicine approaches utilize genetic profiling to guide treatment decisions. Identifying specific genetic mutations and alterations helps match patients with the most suitable therapies, minimizing adverse effects and maximizing therapeutic benefits. Combination therapies are emerging as a promising strategy. These regimens combine different treatment modalities like chemotherapy, targeted agents, and immunotherapies to enhance treatment efficacy and overcome resistance mechanisms. Furthermore, novel drug delivery systems, such as nanoparticles, improve the targeted delivery of therapeutic agents to cancer cells, minimizing damage to healthy tissue. As research continues, these innovative therapeutic approaches are reshaping the Gastric Cancer Therapy Market by offering patients more effective treatments, extending survival, and improving their quality of life.

Innovations in Therapeutic Approaches

Innovations in therapeutic approaches are catalyzing transformative changes in the Global Gastric Cancer Therapy Market. These advancements are redefining the treatment landscape for gastric cancer patients, offering more precise, effective, and personalized interventions. Immunotherapies, especially immune checkpoint inhibitors, are gaining prominence. These therapies empower the immune system to recognize and attack cancer cells, resulting in extended survival and improved outcomes for advanced gastric cancer cases. Targeted therapies are revolutionizing treatment by focusing on specific molecular targets driving cancer growth. Agents like HER2-targeted drugs are tailored to tumors with HER2 overexpression, while VEGF inhibitors disrupt blood vessel formation essential for tumor progression. Precision medicine is leveraging genetic profiling to guide treatment decisions. Identifying genetic mutations and alterations helps match patients with the most suitable therapies, minimizing side effects and maximizing treatment benefits. Combination therapies are emerging as a potent strategy. By combining different treatment modalities like chemotherapy, targeted agents, and immunotherapies, these regimens enhance treatment effectiveness and counter resistance mechanisms. Furthermore, novel drug delivery systems, such as nanoparticles, improve the targeted transport of therapeutic agents to cancer cells, reducing damage to healthy tissue. As research advances, these innovative therapeutic approaches are reshaping the Gastric Cancer Therapy Market, providing patients with more efficacious treatments, prolonging survival, and enhancing their overall quality of life.


Download Free Sample Report


Key Market Challenges

Limited Treatment Options for Advanced Stages

Limited treatment options for advanced stages of gastric cancer pose a significant challenge within the Global Gastric Cancer Therapy Market. Advanced gastric cancer often exhibits aggressive behavior and has typically spread to other parts of the body, reducing the efficacy of standard treatment approaches. Chemotherapy, targeted therapies, and immunotherapies are common treatments, but their effectiveness can diminish as cancer becomes resistant to these interventions. Resistance mechanisms can involve genetic mutations, altered signaling pathways, and immune evasion tactics employed by cancer cells. The complexity of late-stage gastric cancer necessitates the development of innovative therapies to address treatment resistance. Researchers are exploring combination therapies that target multiple pathways simultaneously to overcome resistance and improve treatment outcomes. Additionally, the discovery of new therapeutic targets and the development of novel agents hold promise for expanding treatment options. Clinical trials play a pivotal role in testing and validating these new approaches. By enrolling patients with advanced gastric cancer, these trials contribute to the identification of effective treatments and potentially lead to regulatory approvals for novel therapies. To enhance the treatment landscape for advanced gastric cancer, collaborative efforts among pharmaceutical companies, research institutions, regulatory agencies, and patient advocacy groups are crucial. By addressing the limited treatment options for advanced stages, the Gastric Cancer Therapy Market can improve patient survival rates and quality of life.

Lack of Biomarkers for Treatment Response

The lack of reliable biomarkers for treatment response is a significant challenge in the Global Gastric Cancer Therapy Market. Biomarkers are molecular or genetic indicators that provide insights into disease progression, treatment effectiveness, and potential side effects. In gastric cancer, the absence of well-established biomarkers hinders the ability to predict how individual patients will respond to specific therapies. This lack of predictive biomarkers leads to a "one-size-fits-all" approach to treatment, where patients receive standard therapies without the benefit of tailoring treatment to their unique characteristics. As a result, some patients may not respond optimally to treatments, while others might experience unnecessary side effects.

Researchers are actively investigating potential biomarkers that could guide treatment decisions in gastric cancer. These biomarkers may include genetic mutations, protein expression levels, or molecular signatures specific to the tumor. For example, the HER2 protein's overexpression serves as a biomarker for targeted therapies in certain cases of gastric cancer. The development and validation of reliable biomarkers are complex processes that require extensive clinical research and validation. Challenges include identifying biomarkers that accurately predict treatment response across diverse patient populations and standardizing testing methods to ensure consistency. The integration of precision medicine into the Gastric Cancer Therapy Market relies heavily on identifying biomarkers that indicate which therapies are most likely to succeed for individual patients. Collaborative efforts involving researchers, clinicians, regulatory agencies, and pharmaceutical companies are essential to advancing biomarker discovery, ultimately leading to more personalized and effective treatment strategies for patients with gastric cancer.

Key Market Trends

Immunotherapies Dominance

Immunotherapies' dominance in the Global Gastric Cancer Therapy Market stems from their revolutionary impact on cancer treatment paradigms. Immunotherapy harnesses the body's own immune system to recognize and eliminate cancer cells, offering a fundamentally different approach compared to traditional therapies. In gastric cancer, where treatment options have been limited, immunotherapies have emerged as a beacon of hope. Immune checkpoint inhibitors are a major subset of immunotherapies that have gained significant traction. These drugs target checkpoint proteins like PD-1, PD-L1, and CTLA-4, which cancer cells exploit to evade immune responses. By blocking these proteins, immune checkpoint inhibitors "release the brakes" on the immune system, allowing it to mount a potent attack against cancer cells.

This dominance in the Gastric Cancer Therapy Market is attributed to the remarkable success of immunotherapies in clinical trials. Some patients with advanced gastric cancer who had exhausted other treatment options have experienced prolonged survival and improved quality of life due to immunotherapy. Immunotherapies' efficacy extends beyond advanced cases. Their potential to stimulate long-lasting immune responses has raised interest in combining them with other treatments, such as targeted therapies and chemotherapy, to maximize effectiveness. However, not all patients respond equally to immunotherapies, and some might experience immune-related adverse events. Biomarker discovery is ongoing to identify those most likely to benefit. Collaborative efforts between researchers, pharmaceutical companies, and healthcare providers are essential to refining treatment strategies and expanding access to these transformative therapies. The dominance of immunotherapies signals a paradigm shift in gastric cancer treatment, underscoring the market's rapid evolution and the potential for significantly improved outcomes for patients who previously faced limited options.

Biomarker Development

Biomarker development is a critical aspect of the Global Gastric Cancer Therapy Market, revolutionizing treatment strategies by enabling personalized and targeted approaches. Biomarkers are molecular indicators that provide insights into disease characteristics, treatment responses, and prognosis. In the context of gastric cancer, biomarkers hold immense potential to guide treatment decisions and optimize patient outcomes. Researchers are actively identifying and validating biomarkers that correlate with different aspects of gastric cancer, such as its molecular subtypes, progression, and response to specific therapies. These biomarkers can include genetic mutations, protein expression patterns, and molecular signatures unique to each patient's tumor. Predictive biomarkers are particularly valuable as they help identify patients who are most likely to respond to certain treatments. For instance, HER2 overexpression is a biomarker that predicts response to HER2-targeted therapies in some gastric cancer cases. Prognostic biomarkers aid in estimating the likely course of the disease. Combining predictive and prognostic biomarkers assists in tailoring treatment plans for optimal outcomes. However, biomarker development faces challenges. Biomarkers need to be rigorously validated across diverse patient populations to ensure their accuracy and reliability. Standardizing testing methods and interpretation criteria are essential for consistent results across different laboratories and clinical settings. Advancements in technologies like next-generation sequencing and proteomics are accelerating biomarker discovery. Collaborations between research institutions, pharmaceutical companies, and regulatory bodies facilitate the integration of validated biomarkers into clinical practice, enabling oncologists to make informed treatment decisions. In summary, biomarker development is shaping the Gastric Cancer Therapy Market by guiding personalized treatment strategies and improving patient outcomes. As more biomarkers are discovered, validated, and incorporated into clinical practice, the market's evolution continues toward precision medicine, optimizing therapeutic approaches for gastric cancer patients.

Segmental Insights

Therapeutics Insights

In 2022, the Gastric Cancer Therapy Market was dominated by the targeted therapy segment and is predicted to continue expanding over the coming years. This is attributed due to the rising prevalence of gastric cancer, increasing the demand for effective gastric cancer therapy and drugs, rising product launches and approvals.


Download Free Sample Report

Regional Insights

In 2022, the Global Gastric Cancer Therapy Market was dominated by the North America segment and is predicted to continue expanding over the coming years. This is ascribed due to rising cases gastric ulcers, rising development of gastric cancer therapy, and the growing healthcare infrastructure.

Recent Development

  • In April 2022, BDR Pharmaceuticals introduced Furmecil, an oral generic medication designed for the treatment of advanced gastric cancer.
  • In February 2022, Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb collaborated with Prime Research Institute for Medical RWD, Inc. in a contractual agreement. The collaboration pertains to an industry-sponsored, large-scale, multi-institutional clinical investigation involving patients with gastric cancer who are undergoing treatment with Opdivo in combination with chemotherapy. The study utilizes the data input support system "CyberOncology" developed by PRiME-R, which serves to standardize, organize, manage, and integrate real-world data collected from routine cancer clinical practices.

Key Market Players

  • Abbott Laboratories Inc.
  • Amgen, Inc.
  • Celltrion Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies Inc.
  • AstraZeneca Plc
  • Pfizer Inc.
  • Eli Lilly & Co.
  • GlaxoSmithKline Plc.

By Therapy Type

By End User

By Region
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Radiation Therapy
  • Surgery
  • Ambulatory Surgery Centers
  • Hospitals and Specialty Clinics
  • Other
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

Report Scope:

In this report, the Global Gastric Cancer Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Global Gastric Cancer Therapy Market, By Therapy Type:

o   Chemotherapy

o   Targeted Therapy

o   Immunotherapy

o   Radiation Therapy

o   Surgery

  • Global Gastric Cancer Therapy Market, By End User:

o   Ambulatory Surgery Centers

o   Hospitals and Specialty Clinics

o   Other

  • Global Gastric Cancer Therapy Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

§  Kuwait

§  Turkey

§  Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gastric Cancer Therapy Market.

Available Customizations:

Global Gastric Cancer Therapy Market report with the given Market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional Market players (up to five).

Global Gastric Cancer Therapy Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Types

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, and Trends

4.    Voice of Customer

5.    Global Gastric Cancer Therapy Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value

5.2.  Market Share & Forecast

5.2.1.     By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, and Surgery)

5.2.2.     By End User (Ambulatory Surgery Centers, Hospitals and Specialty Clinics, and Other)

5.2.3.     By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)

5.2.4.     By Company (2022)

5.3.  Product Market Map

5.3.1.     By Therapy Type

5.3.2.     By End User

5.3.3.     By Region

6.    North America Gastric Cancer Therapy Market Outlook

6.1.  Market Size & Forecast          

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Therapy Type

6.2.2.     By End User

6.2.3.     By Country

6.3.  North America: Country Analysis

6.3.1.     United States Gastric Cancer Therapy Market Outlook

6.3.1.1.         Market Size & Forecast

6.3.1.1.1.             By Value

6.3.1.2.         Market Share & Forecast

6.3.1.2.1.             By Therapy Type

6.3.1.2.2.             By End User

6.3.2.     Canada Gastric Cancer Therapy Market Outlook

6.3.2.1.         Market Size & Forecast

6.3.2.1.1.             By Value

6.3.2.2.         Market Share & Forecast

6.3.2.2.1.             By Therapy Type

6.3.2.2.2.             By End User

6.3.3.     Mexico Gastric Cancer Therapy Market Outlook

6.3.3.1.         Market Size & Forecast

6.3.3.1.1.             By Value

6.3.3.2.         Market Share & Forecast

6.3.3.2.1.             By Therapy Type

6.3.3.2.2.             By End User

7.    Europe Gastric Cancer Therapy Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Therapy Type

7.2.2.     By End User

7.2.3.     By Country

7.3.  Europe: Country Analysis

7.3.1.     Germany Gastric Cancer Therapy Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Therapy Type

7.3.1.2.2.             By End User

7.3.2.     France Gastric Cancer Therapy Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Therapy Type

7.3.2.2.2.             By End User

7.3.3.     United Kingdom Gastric Cancer Therapy Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Therapy Type

7.3.3.2.2.             By End User

7.3.4.     Italy Gastric Cancer Therapy Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Therapy Type

7.3.4.2.2.             By End User

7.3.5.     Spain Gastric Cancer Therapy Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Therapy Type

7.3.5.2.2.             By End User

8.    Asia-Pacific Gastric Cancer Therapy Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Therapy Type

8.2.2.     By End User

8.2.3.     By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.     China Gastric Cancer Therapy Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Therapy Type

8.3.1.2.2.             By End User

8.3.2.     Japan Gastric Cancer Therapy Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Therapy Type

8.3.2.2.2.             By End User

8.3.3.     India Gastric Cancer Therapy Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Therapy Type

8.3.3.2.2.             By End User

8.3.4.     South Korea Gastric Cancer Therapy Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Therapy Type

8.3.4.2.2.             By End User

8.3.5.     Australia Gastric Cancer Therapy Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Therapy Type

8.3.5.2.2.             By End User

9.    South America Gastric Cancer Therapy Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Therapy Type

9.2.2.     By End User

9.2.3.     By Country

9.3.  South America: Country Analysis

9.3.1.     Brazil Gastric Cancer Therapy Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Therapy Type

9.3.1.2.2.             By End User

9.3.2.     Argentina Gastric Cancer Therapy Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Therapy Type

9.3.2.2.2.             By End User

9.3.3.     Colombia Gastric Cancer Therapy Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Therapy Type

9.3.3.2.2.             By End User

10.  Middle East and Africa Gastric Cancer Therapy Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Therapy Type

10.2.2.  By End User

10.2.3.  By Country

10.3.              MEA: Country Analysis

10.3.1.  UAE Gastric Cancer Therapy Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Therapy Type

10.3.1.2.2.           By End User

10.3.2.  Saudi Arabia Gastric Cancer Therapy Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Therapy Type

10.3.2.2.2.           By End User

10.3.3.  South Africa Gastric Cancer Therapy Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Therapy Type

10.3.3.2.2.           By End User

11.  Market Dynamics

11.1.              Drivers

11.2.              Challenges

12.  Market Trends & Developments

12.1.              Merger & Acquisition

12.2.              Product Development

12.3.              Recent Developments

13.  Porter’s analysis

14.  PESTEL analysis

15.  Clinical Trial Analysis

15.1.              Ongoing Clinical Trials

15.2.              Completed Clinical Trials

15.3.              Terminated Clinical Trials

15.4.              Breakdown of Pipeline, By Development Phase

15.5.              Breakdown of Pipeline, By Status

15.6.              Breakdown of Pipeline, By Study Application

15.7.              Breakdown of Pipeline, By Region

15.8.              Clinical Trials Heat Map

16.  Competitive Landscape

16.1.              Business Overview

16.2.              Company Snapshot

16.3.              Products & Services

16.4.              Financials (As Reported)

16.5.              Recent Developments

16.5.1.  Abbott Laboratories Inc.

16.5.2.  Amgen, Inc.

16.5.3.  Celltrion Inc.

16.5.4.  Novartis AG

16.5.5.  F. Hoffmann-La Roche Ltd

16.5.6.  Agilent Technologies Inc.

16.5.7.  AstraZeneca Plc

16.5.8.  Pfizer Inc.

16.5.9.  Eli Lilly & Co.

16.5.10.                GlaxoSmithKline Plc

16. Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

The Market size of the Global Gastric Cancer Therapy Market was estimated to be USD 3.51 billion in 2022.

down-arrow

Abbott Laboratories Inc., Amgen, Inc., Celltrion Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., AstraZeneca Plc., Pfizer Inc., Eli Lilly & Co., GlaxoSmithKline Plc etc. are some of the key players operating in the Global Gastric Cancer Therapy Market.

down-arrow

Treatment Resistance, Lack of Biomarkers for Treatment Response, and Healthcare Disparities are some of the major challenges faced by the Global Gastric Cancer Therapy Market in the upcoming years.

down-arrow

Rising Incidence of Gastric Cancer, Advancements in Diagnostic Technologies, Collaboration and Partnerships, Innovations in Therapeutic Approaches, etc. are the major drivers for the Global Gastric Cancer Therapy Market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Gastric Cancer Therapy Market to Grow with a CAGR of 6.13% through 2028

Sep, 2023

Rising prevalence of gastric cancer are expected to drive the Global Gastric Cancer Therapy Market in the forecast period 2024-2028.

Why Choose Us